Mismatch repair deficiency in hematological malignancies with microsatellite instability

被引:40
作者
Gu, LY
Cline-Brown, B
Zhang, FJ
Qiu, L
Li, GM
机构
[1] Univ Kentucky, Ctr Med, Dept Pathol & Lab Med, Lexington, KY 40536 USA
[2] Univ Kentucky, Med Ctr, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA
[3] Univ Kentucky, Med Ctr, Grad Ctr Nutr Sci, Lexington, KY 40536 USA
关键词
hMSH2; hMLH1; microsatellite instability; hematological malignancy;
D O I
10.1038/sj.onc.1205695
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mutations in human mismatch repair (MMR) genes are the genetic basis for certain types of solid tumors displaying microsatellite instability (MSI). MSI has also been observed in hematological malignancies, but whether these hematological malignancies are associated with MMR deficiency is still unclear. Using both biochemical and genetic approaches, this study analysed MMR proficiency in 11 cell lines derived from patients with hematological malignancies and demonstrated that six out of seven hematological cancer cell lines with MSI were defective in strand-specific MMR. In vitro complementation experiments, using characterized MMR mutant extracts or purified proteins, showed that these hematological cancer cells were defective in either hMutSalpha (a heterodimer of hMSH2 and hMSH6) or hMutLalpha (a heterodimer of hMLH1 and hPMS2). Furthermore, cell lines deficient in hMutSalpha showed large deletions or point mutations in hMSH2, while those deficient in hMutLalpha. exhibited point mutations in hMLH1 or a lack of expression of hPMS2. From these results, we conclude that, as in solid tumors, hematological malignancies with MSI are also associated with MMR deficiency, and that the cause of MMR deficiency in these cell lines is due to a defective MutSalpha or MutLalpha. We also report here, for the first time, that an MSI-positive cell line derived from Burkitt's lymphoma is proficient in MMR.
引用
收藏
页码:5758 / 5764
页数:7
相关论文
共 44 条
[1]   CLUES TO THE PATHOGENESIS OF FAMILIAL COLORECTAL-CANCER [J].
AALTONEN, LA ;
PELTOMAKI, P ;
LEACH, FS ;
SISTONEN, P ;
PYLKKANEN, L ;
MECKLIN, JP ;
JARVINEN, H ;
POWELL, SM ;
JEN, J ;
HAMILTON, SR ;
PETERSEN, GM ;
KINZLER, KW ;
VOGELSTEIN, B ;
DELACHAPELLE, A .
SCIENCE, 1993, 260 (5109) :812-816
[2]  
Boland CR, 1998, CANCER RES, V58, P5248
[3]  
BOYER JC, 1995, CANCER RES, V55, P6063
[4]   Mammalian DNA mismatch repair [J].
Buermeyer, AB ;
Deschênes, SM ;
Baker, SM ;
Liskay, RM .
ANNUAL REVIEW OF GENETICS, 1999, 33 :533-564
[5]   Rarity of microsatellite genomic instability in B-cell non-Hodgkin's lymphomas in hepatitis C virus-infected patients [J].
DeVita, S ;
Gasparotto, D ;
Pivetta, B ;
Vukosavljevic, T ;
Zagonel, V ;
Carbone, A ;
Boiocchi, M .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 97 (02) :463-465
[6]   DHFR/MSH3 amplification in methotrexate-resistant cells alters the hMutS alpha/hMutS beta ratio and reduces the efficiency of base-base mismatch repair [J].
Drummond, JT ;
Genschel, J ;
Wolf, E ;
Modrich, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (19) :10144-10149
[7]   ISOLATION OF AN HMSH2-P160 HETERODIMER THAT RESTORES DNA MISMATCH REPAIR TO TUMOR-CELLS [J].
DRUMMOND, JT ;
LI, GM ;
LONGLEY, MJ ;
MODRICH, P .
SCIENCE, 1995, 268 (5219) :1909-1912
[8]   Cisplatin and adriamycin resistance are associated with MutL alpha and mismatch repair deficiency in an ovarian tumor cell line [J].
Drummond, JT ;
Anthoney, A ;
Brown, R ;
Modrich, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (33) :19645-19648
[9]  
Eshleman James R., 1995, Current Opinion in Oncology, V7, P83
[10]   The Saccharomyces cerevisiae MLH3 gene functions in MSH3-dependent suppression of frameshift mutations [J].
Flores-Rozas, H ;
Kolodner, RD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (21) :12404-12409